{"id":"https://openalex.org/W1978242550","doi":"https://doi.org/10.1016/0002-9343(86)90705-9","title":"Recombinant leukocyte A interferon therapy for advanced hairy cell leukemia. Therapeutic and immunologic results","display_name":"Recombinant leukocyte A interferon therapy for advanced hairy cell leukemia. Therapeutic and immunologic results","publication_year":1986,"publication_date":"1986-03-01","ids":{"openalex":"https://openalex.org/W1978242550","doi":"https://doi.org/10.1016/0002-9343(86)90705-9","mag":"1978242550","pmid":"https://pubmed.ncbi.nlm.nih.gov/3953613"},"language":"en","primary_location":{"id":"doi:10.1016/0002-9343(86)90705-9","doi":"https://doi.org/10.1016/0002-9343(86)90705-9","is_oa":false,"landing_page_url":"https://doi.org/10.1016/0002-9343(86)90705-9","pdf_url":null,"source":{"id":"https://openalex.org/S186920367","display_name":"The American Journal of Medicine","issn_l":"0002-9343","issn":["0002-9343","1555-7162"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-2","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"The American Journal of Medicine","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5073403338","display_name":"Kenneth A. Foon","orcid":"https://orcid.org/0000-0002-2748-0986","observed_orcids":["https://orcid.org/0000-0002-2748-0986"]},"institutions":[{"id":"https://openalex.org/I1299303238","display_name":"National Institutes of Health","ror":"https://ror.org/01cwqze88","country_code":"US","type":"government","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1299303238"]},{"id":"https://openalex.org/I4210130649","display_name":"Frederick National Laboratory for Cancer Research","ror":"https://ror.org/03v6m3209","country_code":"US","type":"facility","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1299303238","https://openalex.org/I4210130649","https://openalex.org/I4210140884"]},{"id":"https://openalex.org/I4210140884","display_name":"National Cancer Institute","ror":"https://ror.org/040gcmg81","country_code":"US","type":"government","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1299303238","https://openalex.org/I4210140884"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Kenneth A. Foon","raw_affiliation_strings":["Biological Therapeutics Branch, Biological Response Modifiers Program, Division of Cancer Treatment, National Cancer Institute, National Institutes of Health, and Program Resources, Inc., National Cancer Institute-Frederick Cancer Research Facility, Frederick, Maryland, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Biological Therapeutics Branch, Biological Response Modifiers Program, Division of Cancer Treatment, National Cancer Institute, National Institutes of Health, and Program Resources, Inc., National Cancer Institute-Frederick Cancer Research Facility, Frederick, Maryland, USA","institution_ids":["https://openalex.org/I1299303238","https://openalex.org/I4210130649","https://openalex.org/I4210140884"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5113627210","display_name":"Annette E. Maluish","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1299303238","display_name":"National Institutes of Health","ror":"https://ror.org/01cwqze88","country_code":"US","type":"government","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1299303238"]},{"id":"https://openalex.org/I4210130649","display_name":"Frederick National Laboratory for Cancer Research","ror":"https://ror.org/03v6m3209","country_code":"US","type":"facility","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1299303238","https://openalex.org/I4210130649","https://openalex.org/I4210140884"]},{"id":"https://openalex.org/I4210140884","display_name":"National Cancer Institute","ror":"https://ror.org/040gcmg81","country_code":"US","type":"government","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1299303238","https://openalex.org/I4210140884"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Annette E. Maluish","raw_affiliation_strings":["Biological Therapeutics Branch, Biological Response Modifiers Program, Division of Cancer Treatment, National Cancer Institute, National Institutes of Health, and Program Resources, Inc., National Cancer Institute-Frederick Cancer Research Facility, Frederick, Maryland, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Biological Therapeutics Branch, Biological Response Modifiers Program, Division of Cancer Treatment, National Cancer Institute, National Institutes of Health, and Program Resources, Inc., National Cancer Institute-Frederick Cancer Research Facility, Frederick, Maryland, USA","institution_ids":["https://openalex.org/I1299303238","https://openalex.org/I4210130649","https://openalex.org/I4210140884"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5110498220","display_name":"Paul G. Abrams","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1299303238","display_name":"National Institutes of Health","ror":"https://ror.org/01cwqze88","country_code":"US","type":"government","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1299303238"]},{"id":"https://openalex.org/I4210130649","display_name":"Frederick National Laboratory for Cancer Research","ror":"https://ror.org/03v6m3209","country_code":"US","type":"facility","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1299303238","https://openalex.org/I4210130649","https://openalex.org/I4210140884"]},{"id":"https://openalex.org/I4210140884","display_name":"National Cancer Institute","ror":"https://ror.org/040gcmg81","country_code":"US","type":"government","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1299303238","https://openalex.org/I4210140884"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Paul G. Abrams","raw_affiliation_strings":["Biological Therapeutics Branch, Biological Response Modifiers Program, Division of Cancer Treatment, National Cancer Institute, National Institutes of Health, and Program Resources, Inc., National Cancer Institute-Frederick Cancer Research Facility, Frederick, Maryland, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Biological Therapeutics Branch, Biological Response Modifiers Program, Division of Cancer Treatment, National Cancer Institute, National Institutes of Health, and Program Resources, Inc., National Cancer Institute-Frederick Cancer Research Facility, Frederick, Maryland, USA","institution_ids":["https://openalex.org/I1299303238","https://openalex.org/I4210130649","https://openalex.org/I4210140884"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5018717722","display_name":"Sharyn Wrightington","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1299303238","display_name":"National Institutes of Health","ror":"https://ror.org/01cwqze88","country_code":"US","type":"government","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1299303238"]},{"id":"https://openalex.org/I4210130649","display_name":"Frederick National Laboratory for Cancer Research","ror":"https://ror.org/03v6m3209","country_code":"US","type":"facility","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1299303238","https://openalex.org/I4210130649","https://openalex.org/I4210140884"]},{"id":"https://openalex.org/I4210140884","display_name":"National Cancer Institute","ror":"https://ror.org/040gcmg81","country_code":"US","type":"government","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1299303238","https://openalex.org/I4210140884"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Sharyn Wrightington","raw_affiliation_strings":["Biological Therapeutics Branch, Biological Response Modifiers Program, Division of Cancer Treatment, National Cancer Institute, National Institutes of Health, and Program Resources, Inc., National Cancer Institute-Frederick Cancer Research Facility, Frederick, Maryland, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Biological Therapeutics Branch, Biological Response Modifiers Program, Division of Cancer Treatment, National Cancer Institute, National Institutes of Health, and Program Resources, Inc., National Cancer Institute-Frederick Cancer Research Facility, Frederick, Maryland, USA","institution_ids":["https://openalex.org/I1299303238","https://openalex.org/I4210130649","https://openalex.org/I4210140884"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5113605699","display_name":"Henry C. Stevenson","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1299303238","display_name":"National Institutes of Health","ror":"https://ror.org/01cwqze88","country_code":"US","type":"government","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1299303238"]},{"id":"https://openalex.org/I4210130649","display_name":"Frederick National Laboratory for Cancer Research","ror":"https://ror.org/03v6m3209","country_code":"US","type":"facility","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1299303238","https://openalex.org/I4210130649","https://openalex.org/I4210140884"]},{"id":"https://openalex.org/I4210140884","display_name":"National Cancer Institute","ror":"https://ror.org/040gcmg81","country_code":"US","type":"government","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1299303238","https://openalex.org/I4210140884"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Henry C. Stevenson","raw_affiliation_strings":["Biological Therapeutics Branch, Biological Response Modifiers Program, Division of Cancer Treatment, National Cancer Institute, National Institutes of Health, and Program Resources, Inc., National Cancer Institute-Frederick Cancer Research Facility, Frederick, Maryland, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Biological Therapeutics Branch, Biological Response Modifiers Program, Division of Cancer Treatment, National Cancer Institute, National Institutes of Health, and Program Resources, Inc., National Cancer Institute-Frederick Cancer Research Facility, Frederick, Maryland, USA","institution_ids":["https://openalex.org/I1299303238","https://openalex.org/I4210130649","https://openalex.org/I4210140884"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5074119457","display_name":"Adhid Al-Arif","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1299303238","display_name":"National Institutes of Health","ror":"https://ror.org/01cwqze88","country_code":"US","type":"government","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1299303238"]},{"id":"https://openalex.org/I4210130649","display_name":"Frederick National Laboratory for Cancer Research","ror":"https://ror.org/03v6m3209","country_code":"US","type":"facility","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1299303238","https://openalex.org/I4210130649","https://openalex.org/I4210140884"]},{"id":"https://openalex.org/I4210140884","display_name":"National Cancer Institute","ror":"https://ror.org/040gcmg81","country_code":"US","type":"government","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1299303238","https://openalex.org/I4210140884"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Adhid Alarif","raw_affiliation_strings":["Biological Therapeutics Branch, Biological Response Modifiers Program, Division of Cancer Treatment, National Cancer Institute, National Institutes of Health, and Program Resources, Inc., National Cancer Institute-Frederick Cancer Research Facility, Frederick, Maryland, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Biological Therapeutics Branch, Biological Response Modifiers Program, Division of Cancer Treatment, National Cancer Institute, National Institutes of Health, and Program Resources, Inc., National Cancer Institute-Frederick Cancer Research Facility, Frederick, Maryland, USA","institution_ids":["https://openalex.org/I1299303238","https://openalex.org/I4210130649","https://openalex.org/I4210140884"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5113728031","display_name":"Mehmet F. Fer","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1299303238","display_name":"National Institutes of Health","ror":"https://ror.org/01cwqze88","country_code":"US","type":"government","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1299303238"]},{"id":"https://openalex.org/I4210130649","display_name":"Frederick National Laboratory for Cancer Research","ror":"https://ror.org/03v6m3209","country_code":"US","type":"facility","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1299303238","https://openalex.org/I4210130649","https://openalex.org/I4210140884"]},{"id":"https://openalex.org/I4210140884","display_name":"National Cancer Institute","ror":"https://ror.org/040gcmg81","country_code":"US","type":"government","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1299303238","https://openalex.org/I4210140884"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Mehmet F. Fer","raw_affiliation_strings":["Biological Therapeutics Branch, Biological Response Modifiers Program, Division of Cancer Treatment, National Cancer Institute, National Institutes of Health, and Program Resources, Inc., National Cancer Institute-Frederick Cancer Research Facility, Frederick, Maryland, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Biological Therapeutics Branch, Biological Response Modifiers Program, Division of Cancer Treatment, National Cancer Institute, National Institutes of Health, and Program Resources, Inc., National Cancer Institute-Frederick Cancer Research Facility, Frederick, Maryland, USA","institution_ids":["https://openalex.org/I1299303238","https://openalex.org/I4210130649","https://openalex.org/I4210140884"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5052886428","display_name":"W. Roy Overton","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1299303238","display_name":"National Institutes of Health","ror":"https://ror.org/01cwqze88","country_code":"US","type":"government","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1299303238"]},{"id":"https://openalex.org/I4210130649","display_name":"Frederick National Laboratory for Cancer Research","ror":"https://ror.org/03v6m3209","country_code":"US","type":"facility","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1299303238","https://openalex.org/I4210130649","https://openalex.org/I4210140884"]},{"id":"https://openalex.org/I4210140884","display_name":"National Cancer Institute","ror":"https://ror.org/040gcmg81","country_code":"US","type":"government","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1299303238","https://openalex.org/I4210140884"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"W. Roy Overton","raw_affiliation_strings":["Biological Therapeutics Branch, Biological Response Modifiers Program, Division of Cancer Treatment, National Cancer Institute, National Institutes of Health, and Program Resources, Inc., National Cancer Institute-Frederick Cancer Research Facility, Frederick, Maryland, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Biological Therapeutics Branch, Biological Response Modifiers Program, Division of Cancer Treatment, National Cancer Institute, National Institutes of Health, and Program Resources, Inc., National Cancer Institute-Frederick Cancer Research Facility, Frederick, Maryland, USA","institution_ids":["https://openalex.org/I1299303238","https://openalex.org/I4210130649","https://openalex.org/I4210140884"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5103382996","display_name":"Michael E. Poole","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1299303238","display_name":"National Institutes of Health","ror":"https://ror.org/01cwqze88","country_code":"US","type":"government","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1299303238"]},{"id":"https://openalex.org/I4210130649","display_name":"Frederick National Laboratory for Cancer Research","ror":"https://ror.org/03v6m3209","country_code":"US","type":"facility","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1299303238","https://openalex.org/I4210130649","https://openalex.org/I4210140884"]},{"id":"https://openalex.org/I4210140884","display_name":"National Cancer Institute","ror":"https://ror.org/040gcmg81","country_code":"US","type":"government","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1299303238","https://openalex.org/I4210140884"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Michael Poole","raw_affiliation_strings":["Biological Therapeutics Branch, Biological Response Modifiers Program, Division of Cancer Treatment, National Cancer Institute, National Institutes of Health, and Program Resources, Inc., National Cancer Institute-Frederick Cancer Research Facility, Frederick, Maryland, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Biological Therapeutics Branch, Biological Response Modifiers Program, Division of Cancer Treatment, National Cancer Institute, National Institutes of Health, and Program Resources, Inc., National Cancer Institute-Frederick Cancer Research Facility, Frederick, Maryland, USA","institution_ids":["https://openalex.org/I1299303238","https://openalex.org/I4210130649","https://openalex.org/I4210140884"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5080798996","display_name":"Edward F. Schnipper","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I118019719","display_name":"F. Hoffmann-La Roche AG","ror":"https://ror.org/00by1q217","country_code":"CH","type":"company","lineage":["https://openalex.org/I118019719"]}],"countries":["CH"],"is_corresponding":false,"raw_author_name":"Edward F. Schnipper","raw_affiliation_strings":["Frederick Memorial Hospital, Frederick, Maryland; Hoffmann-La Roche, Inc., Nutley, New Jersey, USA","Frederick Memorial Hospital, Frederick, Maryland","Hoffmann-La Roche, Inc., Nutley, New Jersey, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Frederick Memorial Hospital, Frederick, Maryland; Hoffmann-La Roche, Inc., Nutley, New Jersey, USA","institution_ids":["https://openalex.org/I118019719"]},{"raw_affiliation_string":"Frederick Memorial Hospital, Frederick, Maryland","institution_ids":[]},{"raw_affiliation_string":"Hoffmann-La Roche, Inc., Nutley, New Jersey, USA","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5089779163","display_name":"Elaine S. Jaffe","orcid":"https://orcid.org/0000-0003-4632-0301","observed_orcids":["https://orcid.org/0000-0003-4632-0301"]},"institutions":[{"id":"https://openalex.org/I1299303238","display_name":"National Institutes of Health","ror":"https://ror.org/01cwqze88","country_code":"US","type":"government","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1299303238"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Elaine S. Jaffe","raw_affiliation_strings":["Laboratory of Pathology, Division of Cancer Biology and Diagnosis, National Institutes of Health, Bethesda, Maryland, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Laboratory of Pathology, Division of Cancer Biology and Diagnosis, National Institutes of Health, Bethesda, Maryland, USA","institution_ids":["https://openalex.org/I1299303238"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5112523801","display_name":"Ronald B. Herberman","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1299303238","display_name":"National Institutes of Health","ror":"https://ror.org/01cwqze88","country_code":"US","type":"government","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1299303238"]},{"id":"https://openalex.org/I4210130649","display_name":"Frederick National Laboratory for Cancer Research","ror":"https://ror.org/03v6m3209","country_code":"US","type":"facility","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1299303238","https://openalex.org/I4210130649","https://openalex.org/I4210140884"]},{"id":"https://openalex.org/I4210140884","display_name":"National Cancer Institute","ror":"https://ror.org/040gcmg81","country_code":"US","type":"government","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1299303238","https://openalex.org/I4210140884"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Ronald B. Herberman","raw_affiliation_strings":["Biological Therapeutics Branch, Biological Response Modifiers Program, Division of Cancer Treatment, National Cancer Institute, National Institutes of Health, and Program Resources, Inc., National Cancer Institute-Frederick Cancer Research Facility, Frederick, Maryland, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Biological Therapeutics Branch, Biological Response Modifiers Program, Division of Cancer Treatment, National Cancer Institute, National Institutes of Health, and Program Resources, Inc., National Cancer Institute-Frederick Cancer Research Facility, Frederick, Maryland, USA","institution_ids":["https://openalex.org/I1299303238","https://openalex.org/I4210130649","https://openalex.org/I4210140884"]}]}],"institutions":[],"countries_distinct_count":2,"institutions_distinct_count":4,"corresponding_author_ids":["https://openalex.org/A5073403338"],"corresponding_institution_ids":["https://openalex.org/I1299303238","https://openalex.org/I4210130649","https://openalex.org/I4210140884"],"apc_list":{"value":3770,"currency":"USD","value_usd":3770},"apc_paid":null,"fwci":15.2252,"has_fulltext":false,"cited_by_count":133,"citation_normalized_percentile":{"value":0.9941726,"is_in_top_1_percent":true,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":88,"max":93},"biblio":{"volume":"80","issue":"3","first_page":"351","last_page":"356"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11157","display_name":"Chronic Lymphocytic Leukemia Research","score":0.9750999808311462,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11157","display_name":"Chronic Lymphocytic Leukemia Research","score":0.9750999808311462,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10185","display_name":"Lymphoma Diagnosis and Treatment","score":0.022700000554323196,"subfield":{"id":"https://openalex.org/subfields/2734","display_name":"Pathology and Forensic Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12159","display_name":"T-cell and Retrovirus Studies","score":0.0005000000237487257,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/hairy-cell-leukemia","display_name":"hairy cell leukemia","score":0.996999979019165},{"id":"https://openalex.org/keywords/interferon-therapy","display_name":"interferon therapy","score":0.7129999995231628},{"id":"https://openalex.org/keywords/nk-cell-cytotoxicity","display_name":"NK cell cytotoxicity","score":0.6940000057220459},{"id":"https://openalex.org/keywords/immunologic-recovery","display_name":"immunologic recovery","score":0.7929999828338623},{"id":"https://openalex.org/keywords/hematological-response","display_name":"hematologic response","score":0.7540000081062317},{"id":"https://openalex.org/keywords/splenectomy","display_name":"splenectomy","score":0.8259999752044678},{"id":"https://openalex.org/keywords/monoclonal-antibodies","display_name":"monoclonal antibodies","score":0.7390000224113464},{"id":"https://openalex.org/keywords/lymphoproliferative-disorders","display_name":"lymphoproliferative disorders","score":0.8889999985694885}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.9380496144294739},{"id":"https://openalex.org/C2776309230","wikidata":"https://www.wikidata.org/wiki/Q580383","display_name":"Splenectomy","level":3,"score":0.7644129991531372},{"id":"https://openalex.org/C2780483514","wikidata":"https://www.wikidata.org/wiki/Q201299","display_name":"Hairy cell leukemia","level":3,"score":0.757841944694519},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.6406817436218262},{"id":"https://openalex.org/C2781228144","wikidata":"https://www.wikidata.org/wiki/Q6046441","display_name":"Interferon alfa","level":4,"score":0.5688663721084595},{"id":"https://openalex.org/C2776178377","wikidata":"https://www.wikidata.org/wiki/Q188269","display_name":"Interferon","level":2,"score":0.546911358833313},{"id":"https://openalex.org/C2778461978","wikidata":"https://www.wikidata.org/wiki/Q29496","display_name":"Leukemia","level":2,"score":0.5190999507904053},{"id":"https://openalex.org/C2909179924","wikidata":"https://www.wikidata.org/wiki/Q6046488","display_name":"Alpha interferon","level":3,"score":0.512731671333313},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.4970562756061554},{"id":"https://openalex.org/C2776995267","wikidata":"https://www.wikidata.org/wiki/Q4165484","display_name":"Lymphoproliferative disorders","level":3,"score":0.433817982673645},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.4320524036884308},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.3780706524848938},{"id":"https://openalex.org/C2779338263","wikidata":"https://www.wikidata.org/wiki/Q208414","display_name":"Lymphoma","level":2,"score":0.3142038583755493},{"id":"https://openalex.org/C2780931953","wikidata":"https://www.wikidata.org/wiki/Q9371","display_name":"Spleen","level":2,"score":0.2895911931991577}],"mesh":[{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000368","descriptor_name":"Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000911","descriptor_name":"Antibodies, Monoclonal","qualifier_ui":"Q000276","qualifier_name":"immunology","is_major_topic":false},{"descriptor_ui":"D004305","descriptor_name":"Dose-Response Relationship, Drug","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004334","descriptor_name":"Drug Administration Schedule","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005434","descriptor_name":"Flow Cytometry","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007370","descriptor_name":"Interferon Type I","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D007370","descriptor_name":"Interferon Type I","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D007694","descriptor_name":"Killer Cells, Natural","qualifier_ui":"Q000276","qualifier_name":"immunology","is_major_topic":false},{"descriptor_ui":"D007943","descriptor_name":"Leukemia, Hairy Cell","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D007943","descriptor_name":"Leukemia, Hairy Cell","qualifier_ui":"Q000276","qualifier_name":"immunology","is_major_topic":false},{"descriptor_ui":"D007958","descriptor_name":"Leukocyte Count","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":2,"locations":[{"id":"doi:10.1016/0002-9343(86)90705-9","doi":"https://doi.org/10.1016/0002-9343(86)90705-9","is_oa":false,"landing_page_url":"https://doi.org/10.1016/0002-9343(86)90705-9","pdf_url":null,"source":{"id":"https://openalex.org/S186920367","display_name":"The American Journal of Medicine","issn_l":"0002-9343","issn":["0002-9343","1555-7162"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-2","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"The American Journal of Medicine","raw_type":"journal-article"},{"id":"pmid:3953613","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/3953613","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"The American journal of medicine","raw_type":"Journal Article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","score":0.9907000064849854,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[{"display_name":"Clinical Trial","id":"https://openalex.org/study-designs/clinical-trial"}],"awards":[{"id":"https://openalex.org/G5613954854","display_name":null,"funder_award_id":"N01-CO-12910","funder_id":"https://openalex.org/F4320337351","funder_display_name":"National Cancer Institute"}],"funders":[{"id":"https://openalex.org/F4320337351","display_name":"National Cancer Institute","ror":"https://ror.org/040gcmg81"}],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":25,"referenced_works":["https://openalex.org/W237185628","https://openalex.org/W1528890477","https://openalex.org/W1545320651","https://openalex.org/W1579629308","https://openalex.org/W1605216847","https://openalex.org/W1965931691","https://openalex.org/W1981294686","https://openalex.org/W1995628336","https://openalex.org/W2009099211","https://openalex.org/W2024244869","https://openalex.org/W2030124997","https://openalex.org/W2052677652","https://openalex.org/W2088740471","https://openalex.org/W2090031258","https://openalex.org/W2141278010","https://openalex.org/W2144360148","https://openalex.org/W2324721403","https://openalex.org/W2328766893","https://openalex.org/W2339932366","https://openalex.org/W2343882990","https://openalex.org/W2344245690","https://openalex.org/W2396514826","https://openalex.org/W2411673666","https://openalex.org/W2417690072","https://openalex.org/W4285719527"],"related_works":["https://openalex.org/W2137593192","https://openalex.org/W2053316429","https://openalex.org/W2189430620","https://openalex.org/W7095133252","https://openalex.org/W2039052234","https://openalex.org/W53642436","https://openalex.org/W2462276446","https://openalex.org/W2409203370","https://openalex.org/W2091703047","https://openalex.org/W1995628336"],"abstract_inverted_index":null,"counts_by_year":[{"year":2012,"cited_by_count":1}],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2016-06-24T00:00:00"}